Avacopan for the treatment of ANCA-associated vasculitis

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford). 2011;50(4):697–702.
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–3462.
   PubMed Web of Science ®Google Scholar
• Heeringa P, Tervaert JW. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int. 2004;65(5):1564–1567.
   PubMed Web of Science ®Google Scholar
• Slot MC, Tervaert JW, Franssen CF, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int. 2003;63(2):670–677.
   PubMed Web of Science ®Google Scholar
• Osman MS, Tervaert JWC. Anti-neutrophil cytoplasmic antibodies (ANCA) as disease activity biomarkers in a “personalized medicine approach” in ANCA-associated vasculitis. Curr Rheumatol Rep. 2019;21(12):76.
   PubMed Web of Science ®Google Scholar
• Mendel A, Ennis D, Go E, et al. CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update. J Rheumatol. 2020. DOI:https://doi.org/10.3899/jrheum.200721
   Google Scholar
• Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182.
   PubMed Web of Science ®Google Scholar
• Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976–985.
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2014;66(11):3151–3159.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036–1043.
   PubMed Web of Science ®Google Scholar
• Merkel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662–671.
   PubMedGoogle Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–2767.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609.
   PubMed Web of Science ®Google Scholar
• Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538–547.
   PubMed Web of Science ®Google Scholar
• Lubbers R, Van Essen MF, van Kooten C, et al. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188(2):183–194.
   PubMed Web of Science ®Google Scholar
• Brilland B, Garnier AS, Chevailler A, et al. Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside. Autoimmun Rev. 2020;19(1):102424.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Reis ES, Mastellos DC, et al. Complement component C3 - The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev. 2016;274(1):33–58.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12(7):383–401.
   PubMed Web of Science ®Google Scholar
• O’Flynn J, Dixon KO, Faber Krol MC, et al. Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun. 2014;6(4):417–425.
   PubMed Web of Science ®Google Scholar
• Sethi S, Zand L, De Vriese AS, et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol Dial Transplant. 2017;32(suppl_1):i139–i45.
   PubMedGoogle Scholar
• Kouser L, Abdul-Aziz M, Nayak A, et al. Properdin and factor h: opposing players on the alternative complement pathway “see-saw”. Front Immunol. 2013;4:93.
   PubMed Web of Science ®Google Scholar
• Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117(4):1340–1349.
   PubMed Web of Science ®Google Scholar
• Yuen J, Pluthero FG, Douda DN, et al. NETosing neutrophils activate complement both on their own NETs and bacteria via alternative and non-alternative pathways. Front Immunol. 2016;7:137.
   PubMed Web of Science ®Google Scholar
• Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. Cell Mol Immunol. 2020;17(5):433–450.
   PubMed Web of Science ®Google Scholar
• Miao D, Li DY, Chen M, et al. Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway. Arthritis Res Ther. 2017;19(1):252.
   PubMedGoogle Scholar
• Kraaij T, Kamerling SWA, Van Dam LS, et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney Int. 2018;94(1):139–149.
   PubMed Web of Science ®Google Scholar
• Dick J, Gan PY, Ford SL, et al. C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int. 2018;93(3):615–625.
   PubMed Web of Science ®Google Scholar
• Persson U, Truedsson L, Westman KW, et al. C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis. Clin Exp Immunol. 1999;116(2):379–382.
   PubMed Web of Science ®Google Scholar
• Hilhorst M, van Paassen P, van Rie H, et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2017;32(8):1302–1313.
   PubMed Web of Science ®Google Scholar
• Landowski M, Kelly U, Klingeborn M, et al. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. Proc Natl Acad Sci U S A. 2019;116(9):3703–3711.
   PubMed Web of Science ®Google Scholar
• Su Y, Hu Z, Pan T, et al. Complement factor B gene polymorphisms and risk of age-related macular degeneration: a meta-analysis. Eur J Ophthalmol. 2020;30(4):743–755.
   PubMed Web of Science ®Google Scholar
• Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553–561.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639.
   PubMed Web of Science ®Google Scholar
• Brons RH, Kallenberg CG, Tervaert JW. Are antineutrophil cytoplasmic antibody-associated vasculitides pauci-immune? Rheum Dis Clin North Am. 2001;27(4):833–848.
   PubMed Web of Science ®Google Scholar
• Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29(3):282–291.
   PubMed Web of Science ®Google Scholar
• Fukui S, Iwamoto N, Umeda M, et al. Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis. Medicine (Baltimore). 2016;95(37):e4871.
   PubMed Web of Science ®Google Scholar
• Gou SJ, Yuan J, Chen M, et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83(1):129–137.
   PubMed Web of Science ®Google Scholar
• Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225–231.
   PubMed Web of Science ®Google Scholar
• Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52–64.
   PubMed Web of Science ®Google Scholar
• Gou SJ, Yuan J, Wang C, et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol. 2013;8(11):1884–1891.
   PubMed Web of Science ®Google Scholar
• Chen SF, Wang FM, Li ZY, et al. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther. 2015;17:129.
   PubMed Web of Science ®Google Scholar
• Cheng L, Gou SJ, Qiu HY, et al. Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol. 2018;191(1):116–124.
   PubMed Web of Science ®Google Scholar
• Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71(7):646–654.
   PubMed Web of Science ®Google Scholar
• Wilde B, van Paassen P, Witzke O, et al. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011;79(6):599–612.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20(2):289–298.
   PubMed Web of Science ®Google Scholar
• Freeley SJ, Popat RJ, Parmar K, et al. Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5. J Pathol. 2016;240(1):61–71.
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW. Should proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibody vasculitis be treated differently: part 2. Nephrol Dial Transplant. 2019;34(3):384–387.
   PubMedGoogle Scholar
• Li R, Coulthard LG, Wu MC, et al. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 2013;27(3):855–864.
   PubMed Web of Science ®Google Scholar
• van Werkhoven MB, Damman J, Daha MR, et al. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney. Mol Immunol. 2013;53(3):237–245.
   PubMed Web of Science ®Google Scholar
• Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol. 2011;11(3):187–200.
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. Curr Opin Rheumatol. 2018;30(4):388–394.
   PubMed Web of Science ®Google Scholar
• Stegeman CA, Tervaert JW, de Jong PE, et al., Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med. 1996;335(1):16–20.
   PubMed Web of Science ®Google Scholar
• Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS One. 2016;11(10):e0164646.
   PubMed Web of Science ®Google Scholar
• Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143–1149.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–2803.
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Bosma A, Ng D, et al. D19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5(173): 173–23.
   PubMed Web of Science ®Google Scholar
• Wilde B, Thewissen M, Damoiseaux J, et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis. 2013;72(8):1416–1419.
   PubMed Web of Science ®Google Scholar
• Gan PY, Dick J, O’Sullivan K, et al. Anti-CD20 mAb-induced B cell apoptosis generates T cell regulation of experimental myeloperoxidase ANCA-associated vasculitis. JASN. 2021;32(5):1071–1083.
   Web of Science ®Google Scholar
• Hilhorst M, Wilde B, van Paassen P, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant. 2013;28(2):373–379.
   PubMed Web of Science ®Google Scholar
• Clifford AH, Cohen-Tervaert JW. Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis. Atherosclerosis. 2021;325:8–15.
   PubMed Web of Science ®Google Scholar
• Ennis D, Yeung RS, Pagnoux C. Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. BMJ Case Rep. 2020;13:10.
   Google Scholar
• Carpenter S, Cohen-Tervaert JW, Yacyshyn E. Advances in therapeutic treatment options for ANCA-associated vasculitis. Expert Opin Orphan Drugs. 2020;8:127–136.
   Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–631.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quemeneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients over 65 years. Arthritis Rheumatol. 2015;67(4): 1117–2. DOI:https://doi.org/10.1002/art.39011
   Google Scholar
• Pepper RJ, McAdoo SP, Moran SM, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019 Feb 1;58(2):260–268.
   PubMed Web of Science ®Google Scholar
• Prendecki M, McAdoo SP. New therapeutic targets in antineutrophil cytoplasm antibody-associated vasculitis. Arthritis Rheumatol. 2021 Mar;73(3):361–370.
   PubMed Web of Science ®Google Scholar
• Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319–329.
   PubMed Web of Science ®Google Scholar
• Ender F, Wiese AV, Schmudde I, et al. Differential regulation of C5a receptor 1 in innate immune cells during the allergic asthma effector phase. PLoS One. 2017;12(2):e0172446.
   PubMed Web of Science ®Google Scholar
• Wiese AV, Ender F, Quell KM, et al. The C5a/C5aR1 axis controls the development of experimental allergic asthma independent of LysM-expressing pulmonary immune cells. PLoS One. 2017;12(9):e0184956.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Koehl J. New insights into the role of the complement pathway in allergy and asthma. Curr Allergy Asthma Rep. 2005;5(5):362–369.
   PubMed Web of Science ®Google Scholar
• Vlaar APJ, De Bruin S, Brouwer MC, et al. Efficacy matters: broadening complement inhibition in COVID-19 - Authors’ reply. Lancet Rheumatol. 2021;3(2):e95–e6.
   PubMedGoogle Scholar
• Zetoune FS, Ward PA. Role of Complement and Histones in Sepsis. Front Med (Lausanne). 2020;7:616957.
   PubMed Web of Science ®Google Scholar
• Reddy YN, Siedlecki AM, Francis JM. Breaking down the complement system: a review and update on novel therapies. Curr Opin Nephrol Hypertens. 2017;26(2):123–128.
   PubMed Web of Science ®Google Scholar
• Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp Dermatol. 2020;29(1):86–92.
   PubMed Web of Science ®Google Scholar
• Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020;588(7836):146–150.
   PubMed Web of Science ®Google Scholar
• Ajona D, Zandueta C, Corrales L, et al. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018;197(9):1164–1176.
   PubMed Web of Science ®Google Scholar